Fecal S100A12 as a Biomarker in Behcet’s Disease

Background: Gastroinestinal involvement in Behcet’s disease impacts morbidity and mortality. The diagnosis of gastrointestinal requires comprehensive evaluation with endoscopic radiologic examinations which is costly impractical. A biomarker essential for non-invasive detection. Fecal S100A12 an established inflammatory diseases its serum levels are known to increase Disease. In this study, we aimed tests fecal patients, relation symptoms potential as a involvement. Methods: We prospectively enrolled 48 cases patients fulfilling International Study Group criteria from university hospital. excluded other autoimmune conditions, active or recent infection, using NSAIDs antibiotics. Control group was selected volunteers who had applied the rheumatology outpatient clinic. Patients BD were categorized into 5 groups according organ Also evaluated recorded activity BDCAF 2006. S100A12, calprotectin acute phase reactants also collected. Results: six-fold higher than controls (p<0.0001). two-fold albeit without statistical significance (p=0.132). positively correlated (r:0.530, p<0.0001). Both (138.1 μg/g vs 50.1 μg/g, p=0.006).) (48.3 ng/mL 19.4 ng/mL, p=0.023) Behçet's compared those without. not total score, CRP ESR levels. Conclusion: This first study use symptoms.